Structured evidence table for Nicotinamide Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Nicotinamide Blood Pressure Randomized Trial | These non-pharmaceutical strategies, including nutrient-based and physical approaches, are designed to mitigate cardiovascular risk and prevent progression to overt hypertension []. | 1 | Zhang Mu (2026) | Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Nicotinamide Blood Pressure Randomized Trial | This critical gap between promising biological plausibility and unconfirmed clinical effectiveness necessitates a definitive synthesis of the existing evidence. | 1 | Zhang Mu (2026) | Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Nicotinamide Blood Pressure Randomized Trial | To achieve this, we conducted a systematic review and meta-analysis of all peer-reviewed RCTs to quantify the effects of NMN supplementation on resting SBP and DBP in adults with elevated blood pressure, thereby providing evidence-based conclusions to inform both clinical practice and future research. | 1 | Zhang Mu (2026) | Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Nicotinamide Blood Pressure Randomized Trial | 1 2 3 4 5 6 7 8 9 10 11 10 11 12 13 14 15 16 17 4 18 + + + + The rapid growth of the aging global population has intensified the search for interventions to promote healthy aging. | 1 | Zhang Mu (2026) | Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Nicotinamide Blood Pressure Randomized Trial | Management of glaucoma is now at an inflection point with a new generation of therapeutic candidates, whilst targeting intraocular pressure-independent strategies is challenged by the landmark Phase III failure of memantine regarding trial design and endpoint sensitivity. | 4 | Rho S (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies. |
| Nicotinamide Blood Pressure Randomized Trial | Preclinical research has identified promising targets including glutamate excitotoxicity, neurotrophic factor deprivation, and mitochondrial dysfunction, with nicotinamide emerging as a leading candidate due to its ability to robustly protect RGCs by supporting NAD levels and bioenergetics. | 4 | Rho S (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies. |
Source documents